| Resource | Count |
|---|
| "evidence_1396" | 7 |
| "evidence_1647" | 6 |
| "evidence_1906" | 6 |
| "evidence_1909" | 6 |
| "evidence_1935" | 6 |
| "evidence_1038" | 5 |
| "evidence_1062" | 5 |
| "evidence_1066" | 5 |
| "evidence_1148" | 5 |
| "evidence_1198" | 5 |
| "evidence_1274" | 5 |
| "evidence_1381" | 5 |
| "evidence_1424" | 5 |
| "evidence_1510" | 5 |
| "evidence_1573" | 5 |
| "evidence_1633" | 5 |
| "evidence_1698" | 5 |
| "evidence_1729" | 5 |
| "evidence_1760" | 5 |
| "evidence_1764" | 5 |
| "evidence_1771" | 5 |
| "evidence_1828" | 5 |
| "evidence_1832" | 5 |
| "evidence_1877" | 5 |
| "evidence_1911" | 5 |
| "evidence_1912" | 5 |
| "Avoid thrombi"@en | 4 |
| "evidence_1020" | 4 |
| "evidence_1022" | 4 |
| "evidence_1037" | 4 |
| "evidence_1065" | 4 |
| "evidence_1128" | 4 |
| "evidence_1145" | 4 |
| "evidence_1164" | 4 |
| "evidence_1169" | 4 |
| "evidence_1202" | 4 |
| "evidence_1203" | 4 |
| "evidence_1214" | 4 |
| "evidence_1222" | 4 |
| "evidence_1237" | 4 |
| "evidence_1240" | 4 |
| "evidence_1244" | 4 |
| "evidence_1253" | 4 |
| "evidence_1259" | 4 |
| "evidence_1265" | 4 |
| "evidence_1272" | 4 |
| "evidence_1322" | 4 |
| "evidence_1357" | 4 |
| "evidence_1389" | 4 |
| "evidence_1409" | 4 |
| "evidence_1420" | 4 |
| "evidence_1427" | 4 |
| "evidence_1447" | 4 |
| "evidence_1467" | 4 |
| "evidence_1470" | 4 |
| "evidence_1472" | 4 |
| "evidence_1478" | 4 |
| "evidence_1565" | 4 |
| "evidence_1572" | 4 |
| "evidence_1663" | 4 |
| "evidence_1668" | 4 |
| "evidence_1673" | 4 |
| "evidence_1685" | 4 |
| "evidence_1746" | 4 |
| "evidence_1768" | 4 |
| "evidence_1770" | 4 |
| "evidence_1792" | 4 |
| "evidence_1804" | 4 |
| "evidence_1827" | 4 |
| "evidence_1871" | 4 |
| "evidence_1880" | 4 |
| "evidence_1890" | 4 |
| "evidence_1897" | 4 |
| "evidence_1902" | 4 |
| "evidence_1923" | 4 |
| "evidence_1942" | 4 |
| "evidence_1958" | 4 |
| "evidence_1963" | 4 |
| "evidence_1966" | 4 |
| "evidence_1982" | 4 |
| "evidence_1002" | 3 |
| "evidence_1012" | 3 |
| "evidence_1019" | 3 |
| "evidence_1026" | 3 |
| "evidence_1036" | 3 |
| "evidence_1052" | 3 |
| "evidence_1074" | 3 |
| "evidence_1081" | 3 |
| "evidence_1091" | 3 |
| "evidence_1096" | 3 |
| "evidence_1103" | 3 |
| "evidence_1104" | 3 |
| "evidence_1106" | 3 |
| "evidence_1113" | 3 |
| "evidence_1114" | 3 |
| "evidence_1120" | 3 |
| "evidence_1124" | 3 |
| "evidence_1125" | 3 |
| "evidence_1126" | 3 |
| "evidence_1129" | 3 |
| "evidence_1135" | 3 |
| "evidence_1144" | 3 |
| "evidence_1151" | 3 |
| "evidence_1155" | 3 |
| "evidence_1162" | 3 |
| "evidence_1171" | 3 |
| "evidence_1174" | 3 |
| "evidence_1183" | 3 |
| "evidence_1193" | 3 |
| "evidence_1210" | 3 |
| "evidence_1221" | 3 |
| "evidence_1224" | 3 |
| "evidence_1226" | 3 |
| "evidence_1232" | 3 |
| "evidence_1256" | 3 |
| "evidence_1262" | 3 |
| "evidence_1284" | 3 |
| "evidence_1293" | 3 |
| "evidence_1298" | 3 |
| "evidence_1302" | 3 |
| "evidence_1308" | 3 |
| "evidence_1310" | 3 |
| "evidence_1317" | 3 |
| "evidence_1344" | 3 |
| "evidence_1356" | 3 |
| "evidence_1359" | 3 |
| "evidence_1371" | 3 |
| "evidence_1372" | 3 |
| "evidence_1376" | 3 |
| "evidence_1385" | 3 |
| "evidence_1394" | 3 |
| "evidence_1410" | 3 |
| "evidence_1425" | 3 |
| "evidence_1434" | 3 |
| "evidence_1444" | 3 |
| "evidence_1448" | 3 |
| "evidence_1457" | 3 |
| "evidence_1461" | 3 |
| "evidence_1462" | 3 |
| "evidence_1465" | 3 |
| "evidence_1485" | 3 |
| "evidence_1487" | 3 |
| "evidence_1490" | 3 |
| "evidence_1503" | 3 |
| "evidence_1505" | 3 |
| "evidence_1512" | 3 |
| "evidence_1513" | 3 |
| "evidence_1525" | 3 |
| "evidence_1529" | 3 |
| "evidence_1539" | 3 |
| "evidence_1553" | 3 |
| "evidence_1559" | 3 |
| "evidence_1560" | 3 |
| "evidence_1562" | 3 |
| "evidence_1591" | 3 |
| "evidence_1600" | 3 |
| "evidence_1605" | 3 |
| "evidence_1606" | 3 |
| "evidence_1611" | 3 |
| "evidence_1612" | 3 |
| "evidence_1616" | 3 |
| "evidence_1620" | 3 |
| "evidence_1621" | 3 |
| "evidence_1623" | 3 |
| "evidence_1638" | 3 |
| "evidence_1641" | 3 |
| "evidence_1649" | 3 |
| "evidence_1660" | 3 |
| "evidence_1669" | 3 |
| "evidence_1674" | 3 |
| "evidence_1688" | 3 |
| "evidence_1690" | 3 |
| "evidence_1695" | 3 |
| "evidence_1697" | 3 |
| "evidence_1706" | 3 |
| "evidence_1708" | 3 |
| "evidence_1713" | 3 |
| "evidence_1725" | 3 |
| "evidence_1730" | 3 |
| "evidence_1750" | 3 |
| "evidence_1773" | 3 |
| "evidence_1777" | 3 |
| "evidence_1778" | 3 |
| "evidence_1787" | 3 |
| "evidence_1790" | 3 |
| "evidence_1793" | 3 |
| "evidence_1806" | 3 |
| "evidence_1815" | 3 |
| "evidence_1819" | 3 |
| "evidence_1823" | 3 |
| "evidence_1825" | 3 |
| "evidence_1833" | 3 |
| "evidence_1841" | 3 |
| "evidence_1845" | 3 |
| "evidence_1852" | 3 |
| "evidence_1858" | 3 |
| "evidence_1866" | 3 |
| "evidence_1873" | 3 |
| "evidence_1874" | 3 |
| "evidence_1884" | 3 |
| "evidence_1888" | 3 |
| "evidence_1896" | 3 |
| "evidence_1907" | 3 |
| "evidence_1913" | 3 |
| "evidence_1931" | 3 |
| "evidence_1937" | 3 |
| "evidence_1959" | 3 |
| "evidence_1961" | 3 |
| "evidence_1983" | 3 |
| "evidence_1985" | 3 |
| "evidence_1995" | 3 |
| "Ampicillin" | 2 |
| "Avoid gastrointestinal bleeding"@en | 2 |
| "Bacitracin" | 2 |
| "Bleomycin" | 2 |
| "Bromocriptine" | 2 |
| "Calcium Chloride" | 2 |
| "Carbenicillin" | 2 |
| "Cladribine" | 2 |
| "Clemastine" | 2 |
| "Cycloserine" | 2 |
| "Daunorubicin" | 2 |
| "Dicloxacillin" | 2 |
| "Etomidate" | 2 |
| "Gemcitabine" | 2 |
| "Guanfacine" | 2 |
| "Halothane" | 2 |
| "Imatinib" | 2 |
| "Isosorbide Dinitrate" | 2 |
| "Lindane" | 2 |
| "Mebendazole" | 2 |
| "Mecamylamine" | 2 |
| "Meclizine" | 2 |
| "Meclofenamic acid" | 2 |
| "Meprobamate" | 2 |
| "Methyclothiazide" | 2 |
| "Methyltestosterone" | 2 |
| "Norepinephrine" | 2 |
| "Oxytetracycline" | 2 |
| "Penicillin V" | 2 |
| "Pentostatin" | 2 |
| "Probenecid" | 2 |
| "Procaine" | 2 |
| "Procarbazine" | 2 |
| "Reduce blood pressure"@en | 2 |
| "Reduce blood sugar level"@en | 2 |
| "Reduce pain"@en | 2 |
| "Reserpine" | 2 |
| "Streptomycin" | 2 |
| "Tamoxifen" | 2 |
| "Tolbutamide" | 2 |
| "Topotecan" | 2 |
| "Triamterene" | 2 |
| "Trifluoperazine" | 2 |
| "Vinorelbine" | 2 |
| "Vitamin A" | 2 |
| "chlorpromazine" | 2 |
| "chlorzoxazone" | 2 |
| "diphenhydramine" | 2 |
| "droperidol" | 2 |
| "evidence_1001" | 2 |
| "evidence_1005" | 2 |
| "evidence_1007" | 2 |
| "evidence_1010" | 2 |
| "evidence_1011" | 2 |
| "evidence_1014" | 2 |
| "evidence_1015" | 2 |
| "evidence_1016" | 2 |
| "evidence_1017" | 2 |
| "evidence_1029" | 2 |
| "evidence_1031" | 2 |
| "evidence_1032" | 2 |
| "evidence_1034" | 2 |
| "evidence_1041" | 2 |
| "evidence_1045" | 2 |
| "evidence_1047" | 2 |
| "evidence_1050" | 2 |
| "evidence_1051" | 2 |
| "evidence_1053" | 2 |
| "evidence_1054" | 2 |
| "evidence_1061" | 2 |
| "evidence_1063" | 2 |
| "evidence_1064" | 2 |
| "evidence_1067" | 2 |
| "evidence_1068" | 2 |
| "evidence_1070" | 2 |
| "evidence_1071" | 2 |
| "evidence_1076" | 2 |
| "evidence_1078" | 2 |
| "evidence_1080" | 2 |
| "evidence_1083" | 2 |
| "evidence_1089" | 2 |
| "evidence_1093" | 2 |
| "evidence_1094" | 2 |
| "evidence_1097" | 2 |
| "evidence_1099" | 2 |
| "evidence_1102" | 2 |
| "evidence_1105" | 2 |
| "evidence_1111" | 2 |
| "evidence_1115" | 2 |
| "evidence_1116" | 2 |
| "evidence_1117" | 2 |
| "evidence_1122" | 2 |
| "evidence_1134" | 2 |
| "evidence_1138" | 2 |
| "evidence_1140" | 2 |
| "evidence_1142" | 2 |
| "evidence_1147" | 2 |
| "evidence_1150" | 2 |
| "evidence_1153" | 2 |
| "evidence_1156" | 2 |
| "evidence_1161" | 2 |
| "evidence_1166" | 2 |
| "evidence_1177" | 2 |
| "evidence_1179" | 2 |
| "evidence_1182" | 2 |
| "evidence_1196" | 2 |
| "evidence_1199" | 2 |
| "evidence_1200" | 2 |
| "evidence_1201" | 2 |
| "evidence_1206" | 2 |
| "evidence_1208" | 2 |
| "evidence_1211" | 2 |
| "evidence_1215" | 2 |
| "evidence_1216" | 2 |
| "evidence_1219" | 2 |
| "evidence_1228" | 2 |
| "evidence_1230" | 2 |
| "evidence_1234" | 2 |
| "evidence_1235" | 2 |
| "evidence_1239" | 2 |
| "evidence_1242" | 2 |
| "evidence_1243" | 2 |
| "evidence_1245" | 2 |
| "evidence_1246" | 2 |
| "evidence_1249" | 2 |
| "evidence_1255" | 2 |
| "evidence_1261" | 2 |
| "evidence_1263" | 2 |
| "evidence_1277" | 2 |
| "evidence_1278" | 2 |
| "evidence_1281" | 2 |
| "evidence_1283" | 2 |
| "evidence_1288" | 2 |
| "evidence_1291" | 2 |
| "evidence_1292" | 2 |
| "evidence_1304" | 2 |
| "evidence_1318" | 2 |
| "evidence_1323" | 2 |
| "evidence_1324" | 2 |
| "evidence_1329" | 2 |
| "evidence_1334" | 2 |
| "evidence_1336" | 2 |
| "evidence_1337" | 2 |
| "evidence_1339" | 2 |
| "evidence_1340" | 2 |
| "evidence_1341" | 2 |
| "evidence_1345" | 2 |
| "evidence_1346" | 2 |
| "evidence_1348" | 2 |
| "evidence_1353" | 2 |
| "evidence_1355" | 2 |
| "evidence_1358" | 2 |
| "evidence_1360" | 2 |
| "evidence_1362" | 2 |
| "evidence_1364" | 2 |
| "evidence_1365" | 2 |
| "evidence_1366" | 2 |
| "evidence_1367" | 2 |
| "evidence_1369" | 2 |
| "evidence_1374" | 2 |
| "evidence_1375" | 2 |
| "evidence_1377" | 2 |
| "evidence_1386" | 2 |
| "evidence_1393" | 2 |
| "evidence_1395" | 2 |
| "evidence_1397" | 2 |
| "evidence_1400" | 2 |
| "evidence_1403" | 2 |
| "evidence_1406" | 2 |
| "evidence_1411" | 2 |
| "evidence_1412" | 2 |
| "evidence_1426" | 2 |
| "evidence_1433" | 2 |
| "evidence_1435" | 2 |
| "evidence_1437" | 2 |
| "evidence_1438" | 2 |
| "evidence_1440" | 2 |
| "evidence_1443" | 2 |
| "evidence_1446" | 2 |
| "evidence_1460" | 2 |
| "evidence_1466" | 2 |
| "evidence_1473" | 2 |
| "evidence_1476" | 2 |
| "evidence_1484" | 2 |
| "evidence_1486" | 2 |
| "evidence_1497" | 2 |
| "evidence_1498" | 2 |
| "evidence_1499" | 2 |
| "evidence_1502" | 2 |
| "evidence_1506" | 2 |
| "evidence_1507" | 2 |
| "evidence_1508" | 2 |
| "evidence_1509" | 2 |
| "evidence_1516" | 2 |
| "evidence_1517" | 2 |
| "evidence_1521" | 2 |
| "evidence_1526" | 2 |
| "evidence_1533" | 2 |
| "evidence_1534" | 2 |
| "evidence_1535" | 2 |
| "evidence_1537" | 2 |
| "evidence_1540" | 2 |
| "evidence_1541" | 2 |
| "evidence_1543" | 2 |
| "evidence_1544" | 2 |
| "evidence_1548" | 2 |
| "evidence_1550" | 2 |
| "evidence_1551" | 2 |
| "evidence_1552" | 2 |
| "evidence_1556" | 2 |
| "evidence_1561" | 2 |
| "evidence_1563" | 2 |
| "evidence_1564" | 2 |
| "evidence_1568" | 2 |
| "evidence_1570" | 2 |
| "evidence_1575" | 2 |
| "evidence_1578" | 2 |
| "evidence_1579" | 2 |
| "evidence_1580" | 2 |
| "evidence_1582" | 2 |
| "evidence_1585" | 2 |
| "evidence_1590" | 2 |
| "evidence_1592" | 2 |
| "evidence_1594" | 2 |
| "evidence_1603" | 2 |
| "evidence_1613" | 2 |
| "evidence_1614" | 2 |
| "evidence_1615" | 2 |
| "evidence_1625" | 2 |
| "evidence_1627" | 2 |
| "evidence_1636" | 2 |
| "evidence_1643" | 2 |
| "evidence_1648" | 2 |
| "evidence_1653" | 2 |
| "evidence_1654" | 2 |
| "evidence_1656" | 2 |
| "evidence_1657" | 2 |
| "evidence_1658" | 2 |
| "evidence_1666" | 2 |
| "evidence_1671" | 2 |
| "evidence_1676" | 2 |
| "evidence_1679" | 2 |
| "evidence_1681" | 2 |
| "evidence_1689" | 2 |
| "evidence_1691" | 2 |
| "evidence_1696" | 2 |
| "evidence_1699" | 2 |
| "evidence_1704" | 2 |
| "evidence_1705" | 2 |
| "evidence_1712" | 2 |
| "evidence_1714" | 2 |
| "evidence_1719" | 2 |
| "evidence_1720" | 2 |
| "evidence_1723" | 2 |
| "evidence_1728" | 2 |
| "evidence_1732" | 2 |
| "evidence_1734" | 2 |
| "evidence_1739" | 2 |
| "evidence_1742" | 2 |
| "evidence_1752" | 2 |
| "evidence_1756" | 2 |
| "evidence_1757" | 2 |
| "evidence_1765" | 2 |
| "evidence_1769" | 2 |
| "evidence_1772" | 2 |
| "evidence_1774" | 2 |
| "evidence_1775" | 2 |
| "evidence_1782" | 2 |
| "evidence_1785" | 2 |
| "evidence_1788" | 2 |
| "evidence_1796" | 2 |
| "evidence_1797" | 2 |
| "evidence_1800" | 2 |
| "evidence_1802" | 2 |
| "evidence_1803" | 2 |
| "evidence_1811" | 2 |
| "evidence_1812" | 2 |
| "evidence_1817" | 2 |
| "evidence_1818" | 2 |
| "evidence_1821" | 2 |
| "evidence_1822" | 2 |
| "evidence_1824" | 2 |
| "evidence_1835" | 2 |
| "evidence_1836" | 2 |
| "evidence_1839" | 2 |
| "evidence_1840" | 2 |
| "evidence_1853" | 2 |
| "evidence_1855" | 2 |
| "evidence_1859" | 2 |
| Skipped 13,017 rows |
|---|
| "terbinafine_does_not_inhibit_cyp2d6" | 1 |
| "terbinafine_increases_auc_paroxetine" | 1 |
| "terbinafine_increases_auc_venlafaxine" | 1 |
| "terbinafine_inhibits_cyp2d6" | 1 |
| "terbutaline" | 1 |
| "teriflunomide" | 1 |
| "teriflunomide is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9" | 1 |
| "teriflunomide is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9" | 1 |
| "teriflunomide_does_not_inhibit_cyp2c9" | 1 |
| "teriflunomide_inhibits_cyp2c9" | 1 |
| "tert-butyl 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate" | 1 |
| "tert-butyl [(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]carbamate" | 1 |
| "testicle pain" | 1 |
| "testicular swelling" | 1 |
| "testosterone" | 1 |
| "testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4" | 1 |
| "tetany" | 1 |
| "tetracycline" | 1 |
| "tetrahydrozoline" | 1 |
| "tetralogy of Fallot" | 1 |
| "thalassemia" | 1 |
| "theophylline" | 1 |
| "theophylline_has_metabolite_1,3-dimethyluric-acid" | 1 |
| "theophylline_has_metabolite_1-methylxanthine" | 1 |
| "theophylline_has_metabolite_3-methylxanthine" | 1 |
| "theophylline_has_metabolite_caffeine" | 1 |
| "theophylline_in_vitro_probe_substrate_of_enzyme_cyp1a2" | 1 |
| "theophylline_primary_total_clearance_enzyme_cyp1a2" | 1 |
| "theophylline_primary_total_clearance_mechanism_Metabolic_Clearance" | 1 |
| "therapeutic abortion" | 1 |
| "thiabendazole" | 1 |
| "thinking abnormal" | 1 |
| "thioridazine-5-sulfoxide" | 1 |
| "thioridazine_does_not_inhibit_cyp2c19" | 1 |
| "thioridazine_has_metabolite_mesoridazine" | 1 |
| "thioridazine_has_metabolite_sulforidazine" | 1 |
| "thioridazine_has_metabolite_thioridazine-5-sulfoxide" | 1 |
| "thioridazine_inhibition_constant_cyp2d6" | 1 |
| "thioridazine_inhibits_cyp2c19" | 1 |
| "thioridazine_is_not_substrate_of_cyp2d6" | 1 |
| "thioridazine_primary_total_clearance_enzyme_cyp2d6" | 1 |
| "thioridazine_substrate_of_cyp2d6" | 1 |
| "thiotepa" | 1 |
| "thiothixene" | 1 |
| "thiothixene_does_not_inhibit_cyp2c19" | 1 |
| "thiothixene_inhibition_constant_cyp2d6" | 1 |
| "thiothixene_inhibits_cyp2c19" | 1 |
| "thoracotomy" | 1 |
| "threadworm" | 1 |
| "threohydrobupropion" | 1 |
| "threohydrobupropion_maximum_concentration_continuous_value" | 1 |
| "threohydrobupropion_primary_total_clearance_mechanism_Renal_Excretion" | 1 |
| "thromboangiitis obliterans" | 1 |
| "thrombophilia" | 1 |
| "thrombophlebitis" | 1 |
| "thrombophlebitis superficial" | 1 |
| "thrombotic thrombocytopenic purpura" | 1 |
| "thyroid adenoma" | 1 |
| "thyroid disorder" | 1 |
| "thyroid neoplasia" | 1 |
| "thyroid nodules" | 1 |
| "thyroidectomy" | 1 |
| "thyroiditis" | 1 |
| "thyrotoxicosis" | 1 |
| "ticlopidine" | 1 |
| "ticlopidine increases the AUC of bupropion" | 1 |
| "ticlopidine_increases_auc_bupropion" | 1 |
| "ticlopidine_inhibition_constant_cyp2b6" | 1 |
| "ticlopidine_inhibition_constant_cyp2c19" | 1 |
| "tiludronic acid" | 1 |
| "tinnitus" | 1 |
| "tolazamide" | 1 |
| "tolazoline" | 1 |
| "tolbutamide" | 1 |
| "tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9" | 1 |
| "tolbutamide_primary_total_clearance_enzyme_cyp2c9" | 1 |
| "tolmetin" | 1 |
| "tongue carcinoma" | 1 |
| "tonsillectomy" | 1 |
| "tooth caries" | 1 |
| "tooth disorder" | 1 |
| "topiramate" | 1 |
| "topiramate_does_not_inhibit_cyp1a2" | 1 |
| "topiramate_does_not_inhibit_cyp2a6" | 1 |
| "topiramate_does_not_inhibit_cyp2b6" | 1 |
| "topiramate_does_not_inhibit_cyp2c19" | 1 |
| "topiramate_does_not_inhibit_cyp2c9" | 1 |
| "topiramate_does_not_inhibit_cyp2d6" | 1 |
| "topiramate_does_not_inhibit_cyp2e1" | 1 |
| "topiramate_does_not_inhibit_cyp3a4" | 1 |
| "topiramate_does_not_inhibit_cyp3a5" | 1 |
| "topiramate_inhibits_cyp1a2" | 1 |
| "topiramate_inhibits_cyp2a6" | 1 |
| "topiramate_inhibits_cyp2b6" | 1 |
| "topiramate_inhibits_cyp2c19" | 1 |
| "topiramate_inhibits_cyp2c9" | 1 |
| "topiramate_inhibits_cyp2d6" | 1 |
| "topiramate_inhibits_cyp2e1" | 1 |
| "topiramate_inhibits_cyp3a4" | 1 |
| "topiramate_inhibits_cyp3a5" | 1 |
| "topiramate_primary_total_clearance_mechanism_Renal_Excretion" | 1 |
| "toremifene" | 1 |
| "torsemide" | 1 |
| "torticollis" | 1 |
| "toxic epidermal necrolysis" | 1 |
| "toxic goiter" | 1 |
| "toxic shock syndrome" | 1 |
| "tracheitis" | 1 |
| "tracheobronchitis" | 1 |
| "tracheostomy" | 1 |
| "trans NV-04" | 1 |
| "trans-2-hydroxycinnamic acid" | 1 |
| "trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium" | 1 |
| "trans-urocanic acid" | 1 |
| "transdermal testosterone gel" | 1 |
| "transient amnesia" | 1 |
| "transient cerebral ischemia" | 1 |
| "transient global amnesia" | 1 |
| "transient hallucinations" | 1 |
| "transient ischemic attack" | 1 |
| "transposition of the great vessels" | 1 |
| "transurethral resection of the prostate" | 1 |
| "transverse myelitis" | 1 |
| "trauma" | 1 |
| "trazodone" | 1 |
| "trazodone_bioavailability_continuous_value" | 1 |
| "trazodone_has_metabolite_M-chlorophenylpiperazine" | 1 |
| "trazodone_is_not_substrate_of_cyp3a4" | 1 |
| "trazodone_maximum_concentration_continuous_value" | 1 |
| "trazodone_primary_total_clearance_mechanism_Renal_Excretion" | 1 |
| "trazodone_substrate_of_cyp3a4" | 1 |
| "triacetyl uridine" | 1 |
| "triazolam" | 1 |
| "triazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4" | 1 |
| "triazolam_increases_auc_nefazodone" | 1 |
| "triazolam_primary_total_clearance_enzyme_cyp3a4" | 1 |
| "tributylstannanyl" | 1 |
| "trichomonal vaginitis" | 1 |
| "trifascicular block" | 1 |
| "trifluoperazine" | 1 |
| "trigger finger" | 1 |
| "trimethoprim" | 1 |
| "trimethoprim is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C8" | 1 |
| "trimethoprim_does_not_inhibit_cyp2c8" | 1 |
| "trimethoprim_inhibits_cyp2c8" | 1 |
| "tripotassium (1R)-4-biphenyl-4-yl-1-phosphonatobutane-1-sulfonate" | 1 |
| "troleandomycin" | 1 |
| "troleandomycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4" | 1 |
| "tropical sprue" | 1 |
| "tropicamide" | 1 |
| "trovafloxacin" | 1 |
| "tubal ligation" | 1 |
| "tubal pregnancy" | 1 |
| "ulcerative proctitis" | 1 |
| "ulcerative stomatitis" | 1 |
| "umbilical hernia" | 1 |
| "unconsciousness" | 1 |
| "undecan-2-one" | 1 |
| "unsteady gait" | 1 |
| "upper GI bleeding" | 1 |
| "upper respiratory tract infection" | 1 |
| "urate crystalluria" | 1 |
| "uremia" | 1 |
| "ureteral obstruction" | 1 |
| "urinary frequency" | 1 |
| "urinary hesitancy" | 1 |
| "urinary incontinence" | 1 |
| "urinary obstruction" | 1 |
| "urinary outflow obstruction" | 1 |
| "urinary urgency" | 1 |
| "urogenital anomaly" | 1 |
| "urolithiasis" | 1 |
| "urosepsis" | 1 |
| "uterine hemorrhage" | 1 |
| "uterine sarcoma" | 1 |
| "vaginal discharge" | 1 |
| "vaginal dysplasia" | 1 |
| "vaginal hemorrhage" | 1 |
| "vaginal hysterectomy" | 1 |
| "vaginal moniliasis" | 1 |
| "vaginal pruritus" | 1 |
| "vaginitis" | 1 |
| "valproate" | 1 |
| "valproate increases the AUC of hydroxybupropion" | 1 |
| "valproate_increases_auc_aripiprazole" | 1 |
| "valproate_increases_auc_bupropion" | 1 |
| "valproate_increases_auc_hydroxybupropion" | 1 |
| "valproate_primary_total_clearance_mechanism_Metabolic_Clearance" | 1 |
| "valvular heart disease" | 1 |
| "vapitadine dihydrochloride" | 1 |
| "varicocele" | 1 |
| "varicose vein" | 1 |
| "vascular anomaly" | 1 |
| "vascular headache" | 1 |
| "vasovagal reaction" | 1 |
| "vegetarian" | 1 |
| "venereal disease" | 1 |
| "venlafaxine" | 1 |
| "venlafaxine increases the AUC of desipramine" | 1 |
| "venlafaxine increases the AUC of haloperidol" | 1 |
| "venlafaxine increases the AUC of imipramine" | 1 |
| "venlafaxine increases the AUC of risperidone" | 1 |
| "venlafaxine is predicted to reduce the clearance of aripiprazole by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of clozapine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of desipramine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of duloxetine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of escitalopram by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of fluoxetine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of fluvoxamine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of iloperidone by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of mirtazapine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of olanzapine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of paroxetine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of perphenazine by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of r-citalopram by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of risperidone by inhibition of CYP2D6" | 1 |
| "venlafaxine is predicted to reduce the clearance of thioridazine by inhibition of CYP2D6" | 1 |
| "venlafaxine_does_not_inhibit_cyp1a2" | 1 |
| "venlafaxine_does_not_inhibit_cyp2c9" | 1 |
| "venlafaxine_does_not_inhibit_cyp2d6" | 1 |
| "venlafaxine_does_not_inhibit_cyp3a4" | 1 |
| "venlafaxine_fraction_absorbed_continuous_value" | 1 |
| "venlafaxine_has_metabolite_N-desmethylvenlafaxine" | 1 |
| "venlafaxine_has_metabolite_O-desmethylvenlafaxine" | 1 |
| "venlafaxine_increases_auc_9-hydroxyrisperidone" | 1 |
| "venlafaxine_increases_auc_alprazolam" | 1 |
| "venlafaxine_increases_auc_desipramine" | 1 |
| "venlafaxine_increases_auc_haloperidol" | 1 |
| "venlafaxine_increases_auc_imipramine" | 1 |
| "venlafaxine_increases_auc_risperidone" | 1 |
| "venlafaxine_inhibits_cyp1a2" | 1 |
| "venlafaxine_inhibits_cyp2c9" | 1 |
| "venlafaxine_inhibits_cyp2d6" | 1 |
| "venlafaxine_inhibits_cyp3a4" | 1 |
| "venlafaxine_is_not_substrate_of_cyp2d6" | 1 |
| "venlafaxine_is_not_substrate_of_cyp3a4" | 1 |
| "venlafaxine_maximum_concentration_continuous_value" | 1 |
| "venlafaxine_primary_total_clearance_enzyme_cyp2d6" | 1 |
| "venlafaxine_primary_total_clearance_mechanism_Metabolic_Clearance" | 1 |
| "venlafaxine_substrate_of_cyp2d6" | 1 |
| "venlafaxine_substrate_of_cyp3a4" | 1 |
| "venous insufficiency" | 1 |
| "venous thrombosis" | 1 |
| "ventricular extrasystoles" | 1 |
| "ventricular fibrillation" | 1 |
| "ventricular tachycardia" | 1 |
| "verapamil" | 1 |
| "verapamil increases the AUC of imipramine" | 1 |
| "verapamil increases the AUC of risperidone" | 1 |
| "verapamil is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of alprazolam by inhibition of CYP3A5" | 1 |
| "verapamil is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of clozapine by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of duloxetine by inhibition of CYP1A2" | 1 |
| "verapamil is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of mirtazapine by inhibition of CYP1A2" | 1 |
| "verapamil is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A5" | 1 |
| "verapamil is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of perphenazine by inhibition of CYP1A2" | 1 |
| "verapamil is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of risperidone by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of trazodone by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of triazolam by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4" | 1 |
| "verapamil is predicted to reduce the clearance of zolpidem by inhibition of CYP3A5" | 1 |
| "verapamil_does_not_inhibit_cyp1a2" | 1 |
| "verapamil_does_not_inhibit_cyp3a4" | 1 |
| "verapamil_does_not_inhibit_cyp3a5" | 1 |
| "verapamil_increases_auc_imipramine" | 1 |
| "verapamil_increases_auc_risperidone" | 1 |
| "verapamil_inhibits_cyp1a2" | 1 |
| "verapamil_inhibits_cyp3a4" | 1 |
| "verapamil_inhibits_cyp3a5" | 1 |
| "verruca" | 1 |
| "vertebral fracture" | 1 |
| "viral hepatitis" | 1 |
| "viral infection" | 1 |
| "viral syndrome" | 1 |
| "visual field defect" | 1 |
| "visual hallucinations" | 1 |
| "visual halos" | 1 |
| "vitamin B deficiency" | 1 |
| "vitamin B12 deficiency" | 1 |
| "vitamin deficiency" | 1 |
| "vitreous detachment" | 1 |
| "vitreous floaters" | 1 |
| "vitreous hemorrhage" | 1 |
| "vocal cord paralysis" | 1 |
| "voice alteration" | 1 |
| "volvulus" | 1 |
| "von Willebrand disease" | 1 |
| "voriconazole" | 1 |
| "voriconazole is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of citalopram by inhibition of CYP2C19" | 1 |
| "voriconazole is predicted to reduce the clearance of clozapine by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9" | 1 |
| "voriconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of risperidone by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9" | 1 |
| "voriconazole is predicted to reduce the clearance of sertraline by inhibition of CYP2C19" | 1 |
| "voriconazole is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of trazodone by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of triazolam by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4" | 1 |
| "voriconazole is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4" | 1 |
| "voriconazole-N-oxide" | 1 |
| "voriconazole-N-oxide_does_not_inhibit_cyp2c19" | 1 |
| "voriconazole-N-oxide_does_not_inhibit_cyp2c9" | 1 |
| "voriconazole-N-oxide_does_not_inhibit_cyp3a4" | 1 |
| "voriconazole-N-oxide_inhibits_cyp2c19" | 1 |
| "voriconazole-N-oxide_inhibits_cyp2c9" | 1 |
| "voriconazole-N-oxide_inhibits_cyp3a4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of citalopram by inhibition of CYP2C19" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of clozapine by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of risperidone by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of sertraline by inhibition of CYP2C19" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of trazodone by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of triazolam by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4" | 1 |
| "voriconazole-n-oxide is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4" | 1 |
| "voriconazole_bioavailability_continuous_value" | 1 |
| "voriconazole_does_not_inhibit_cyp2c19" | 1 |
| "voriconazole_does_not_inhibit_cyp2c9" | 1 |
| "voriconazole_does_not_inhibit_cyp3a4" | 1 |
| "voriconazole_has_metabolite_voriconazole-N-oxide" | 1 |
| "voriconazole_inhibits_cyp2c19" | 1 |
| "voriconazole_inhibits_cyp2c9" | 1 |
| "voriconazole_inhibits_cyp3a4" | 1 |
| "voriconazole_is_not_substrate_of_cyp2c19" | 1 |
| "voriconazole_is_not_substrate_of_cyp2c9" | 1 |
| "voriconazole_is_not_substrate_of_cyp3a4" | 1 |
| "voriconazole_maximum_concentration_continuous_value" | 1 |
| "voriconazole_primary_total_clearance_enzyme_cyp2c19" | 1 |
| "voriconazole_primary_total_clearance_mechanism_Metabolic_Clearance" | 1 |
| "voriconazole_substrate_of_cyp2c19" | 1 |
| "voriconazole_substrate_of_cyp2c9" | 1 |
| "voriconazole_substrate_of_cyp3a4" | 1 |
| "vulval abscess" | 1 |
| "vulvitis" | 1 |
| "vulvovaginitis" | 1 |
| "warfarin" | 1 |
| "warfarin_primary_total_clearance_enzyme_cyp2c9" | 1 |
| "watery eyes" | 1 |
| "weakness" | 1 |
| "weight gain" | 1 |
| "wheezing" | 1 |
| "white blood cell count increased" | 1 |
| "worry" | 1 |
| "wound dehiscence" | 1 |
| "wrist pain" | 1 |
| "xanthomas" | 1 |
| "xerosis" | 1 |
| "zafirlukast" | 1 |
| "zafirlukast is predicted to reduce the clearance of alprazolam by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of aripiprazole by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of clozapine by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of escitalopram by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of eszopiclone by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9" | 1 |
| "zafirlukast is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of haloperidol by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of iloperidone by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of mirtazapine by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of nefazodone by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of perphenazine by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of r-citalopram by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of reduced-haloperidol by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of risperidone by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9" | 1 |
| "zafirlukast is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of trazodone by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of triazolam by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of venlafaxine by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of zaleplon by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of ziprasidone by inhibition of CYP3A4" | 1 |
| "zafirlukast is predicted to reduce the clearance of zolpidem by inhibition of CYP3A4" | 1 |
| "zafirlukast_does_not_inhibit_cyp2c9" | 1 |
| "zafirlukast_does_not_inhibit_cyp3a4" | 1 |
| "zafirlukast_inhibits_cyp2c9" | 1 |
| "zafirlukast_inhibits_cyp3a4" | 1 |
| "zafirlukast_is_not_substrate_of_cyp2c9" | 1 |
| "zafirlukast_maximum_concentration_continuous_value" | 1 |
| "zafirlukast_substrate_of_cyp2c9" | 1 |
| "zaleplon" | 1 |
| "zaleplon_bioavailability_continuous_value" | 1 |
| "zaleplon_is_not_substrate_of_cyp2d6" | 1 |
| "zaleplon_is_not_substrate_of_cyp3a4" | 1 |
| "zaleplon_primary_total_clearance_mechanism_Metabolic_Clearance" | 1 |
| "zaleplon_substrate_of_cyp2d6" | 1 |
| "zaleplon_substrate_of_cyp3a4" | 1 |
| "zileuton" | 1 |
| "ziprasidone" | 1 |
| "ziprasidone-sulphoxide" | 1 |
| "ziprasidone_does_not_inhibit_cyp1a2" | 1 |
| "ziprasidone_does_not_inhibit_cyp2c19" | 1 |
| "ziprasidone_does_not_inhibit_cyp2c9" | 1 |
| "ziprasidone_does_not_inhibit_cyp2d6" | 1 |
| "ziprasidone_does_not_inhibit_cyp3a4" | 1 |
| "ziprasidone_has_metabolite_S-methyl-dihydroziprasidone" | 1 |
| "ziprasidone_has_metabolite_benzisothiazole-sulphone" | 1 |
| "ziprasidone_has_metabolite_benzisothiazole-sulphoxide" | 1 |
| "ziprasidone_has_metabolite_ziprasidone-sulphoxide" | 1 |
| "ziprasidone_inhibition_constant_cyp2d6" | 1 |
| "ziprasidone_inhibits_cyp1a2" | 1 |
| "ziprasidone_inhibits_cyp2c19" | 1 |
| "ziprasidone_inhibits_cyp2c9" | 1 |
| "ziprasidone_inhibits_cyp2d6" | 1 |
| "ziprasidone_inhibits_cyp3a4" | 1 |
| "ziprasidone_is_not_substrate_of_cyp1a2" | 1 |
| "ziprasidone_is_not_substrate_of_cyp2c19" | 1 |
| "ziprasidone_is_not_substrate_of_cyp2c9" | 1 |
| "ziprasidone_is_not_substrate_of_cyp2d6" | 1 |
| "ziprasidone_is_not_substrate_of_cyp3a4" | 1 |
| "ziprasidone_maximum_concentration_continuous_value" | 1 |
| "ziprasidone_primary_total_clearance_mechanism_Metabolic_Clearance" | 1 |
| "ziprasidone_substrate_of_cyp1a2" | 1 |
| "ziprasidone_substrate_of_cyp2c19" | 1 |
| "ziprasidone_substrate_of_cyp2c9" | 1 |
| "ziprasidone_substrate_of_cyp2d6" | 1 |
| "ziprasidone_substrate_of_cyp3a4" | 1 |
| "zolpidem" | 1 |
| "zolpidem_is_not_substrate_of_cyp3a4" | 1 |
| "zolpidem_is_not_substrate_of_cyp3a5" | 1 |
| "zolpidem_maximum_concentration_continuous_value" | 1 |
| "zolpidem_substrate_of_cyp3a4" | 1 |
| "zolpidem_substrate_of_cyp3a5" | 1 |
| "{(1s)-1-Benzyl-4-[3-Carbamoyl-1-(1-Carbamoyl-2-Phenyl-Ethylcarbamoyl)-(S)-Propylcarbamoyl]-2-Oxo-5-Phenyl-Pentyl}-Carbamic Acid Tert-Butyl Ester" | 1 |
| "{(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate" | 1 |
| "{(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide" | 1 |
| "{(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE" | 1 |
| "{1-[(3-Hydroxy-Methyl-5-Phosphonooxy-Methyl-Pyridin-4-Ylmethyl)-Amino]-Ethyl}-Phosphonic Acid" | 1 |
| "{1-[2-(1-FORMYL-PROPYL)-3-METHANESULFONYLAMINO-PYRROLIDINE-1-CARBONYL]-2-METHYL-PROPYL}-CARBAMIC ACID TERT-BUTYL ESTER" | 1 |
| "{3-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-2-Methyl-Propyl}-Phosphonic Acid" | 1 |
| "{3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID" | 1 |
| "{3-[(5-CHLORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL}ACETIC ACID" | 1 |
| "{3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid" | 1 |
| "{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone" | 1 |
| "{4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid" | 1 |
| "{4-[(CARBOXYMETHOXY)CARBONYL]-3,3-DIOXIDO-1-OXONAPHTHO[1,2-D]ISOTHIAZOL-2(1H)-YL}ACETIC ACID" | 1 |
| "{4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID" | 1 |
| "{4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid" | 1 |
| "{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID" | 1 |
| "{4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid" | 1 |
| "{4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol" | 1 |
| "{4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid" | 1 |
| "{5-(5-AMINO-1H-PYRROLO[3,2-B]PYRIDIN-2-YL)-6-HYDROXY-3'-NITRO-BIPHENYL-3-YL]-ACETIC ACID" | 1 |
| "{[(2,2-Dihydroxy-Ethyl)-(2,3,4,5-Tetrahydroxy-6-Phosphonooxy-Hexyl)-Amino]-Methyl}-Phosphonic Acid" | 1 |
| "{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide" | 1 |
| "{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)" | 1 |
| "{[4-AMINO-2-(3-CHLOROANILINO)-1,3-THIAZOL-5-YL](4-FLUOROPHENYL)METHANONE" | 1 |
| "{[5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOL-2-YL]THIO}ACETIC ACID" | 1 |
| "{[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid" | 1 |
